Get the Stockscreener App
5.47
3.36%
-0.19
After Hours:
5.47
Solid Biosciences Inc stock is traded at $5.47, with a volume of 902.06K.
It is down -3.36% in the last 24 hours and down -6.01% over the past month.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
See More
Previous Close:
$5.66
Open:
$5.64
24h Volume:
902.06K
Relative Volume:
0.87
Market Cap:
$426.17M
Revenue:
$14.79M
Net Income/Loss:
$-102.44M
P/E Ratio:
-1.7993
EPS:
-3.04
Net Cash Flow:
$-91.73M
1W Performance:
+3.40%
1M Performance:
-6.01%
6M Performance:
-1.97%
1Y Performance:
+68.31%
1-Day Range:
$5.4099
$5.745
1-Week Range:
$4.92
$5.96
52-Week Range:
$2.41
$7.37
Solid Biosciences Inc Stock (SLDB) Company Profile
Name
Solid Biosciences Inc
Sector
Industry
Phone
617-337-4680
Address
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
5.47 | 440.97M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-25 | Initiated | Needham | Buy |
| Jun-26-25 | Initiated | Citigroup | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-13-24 | Initiated | Wedbush | Outperform |
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-15-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | William Blair | Outperform |
| Mar-15-24 | Initiated | Citigroup | Buy |
| Mar-14-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | Piper Sandler | Neutral |
| May-27-21 | Initiated | Jefferies | Buy |
| Mar-16-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jul-28-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-07-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-19 | Initiated | Evercore ISI | Outperform |
| Aug-29-19 | Downgrade | Citigroup | Neutral → Sell |
| Aug-19-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-16-19 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| May-14-19 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-14-19 | Downgrade | Goldman | Neutral → Sell |
| Feb-08-19 | Upgrade | Citigroup | Sell → Neutral |
| Feb-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-06-18 | Initiated | Citigroup | Sell |
| Sep-06-18 | Initiated | Credit Suisse | Neutral |
View All
Solid Biosciences Inc Stock (SLDB) Latest News
Aug Rallies: Is ITRI stock undervalued right now2025 Breakouts & Breakdowns & Consistent Growth Equity Picks - baoquankhu1.vn
Risk Recap: Whats the beta of Solid Biosciences Inc stockJuly 2025 Institutional & Community Verified Watchlist Alerts - baoquankhu1.vn
Phase 1b Trial for Solid Biosciences’ Friedreich Ataxia Gene Therapy SGT-212 Doses First Patient - NeurologyLive
Solid Biosciences director Ilan Ganot sells $447 in stock - MSN
Solid Bio rises as Duchenne study gets fully enrolled - MSN
JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success - Pharmaceutical Technology
FOMO Trade: Does Solid Biosciences Inc offer margin of safetyQuarterly Profit Summary & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Solid Biosciences (SLDB) Completes Enrollment in Key Duchenne St - GuruFocus
Needham Reiterates Buy Rating on SLDB with Price Target of $16.0 - GuruFocus
Needham & Company LLC Reiterates "Buy" Rating for Solid Biosciences (NASDAQ:SLDB) - MarketBeat
Solid Bio fully enrolls Duchenne study for lead drug (SLDB) - Seeking Alpha
Solid Biosciences advances gene therapy trials for rare diseases By Investing.com - Investing.com Nigeria
Solid Biosciences (SLDB) Completes Enrollment for SGT-003 Clinical Trial - Intellectia AI
Solid Biosciences (NASDAQ:SLDB) CFO Kevin Tan Sells 5,704 Shares - MarketBeat
Solid Biosciences advances gene therapy trials for rare diseases - Investing.com
Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101 - The Manila Times
Rare disease gene trials grow as Solid Biosciences inks 50+ capsid pacts - Stock Titan
Solid Biosciences doses first participant in Friedreich’s ataxia trial By Investing.com - Investing.com Nigeria
Solid Biosciences receives FDA orphan drug designation for FA therapy By Investing.com - Investing.com Nigeria
Solid Biosciences Gets Orphan Drug Label for SGT-212 to Treat Friedreich's Ataxia - marketscreener.com
SLDB Gains FDA Orphan Drug Designation for SGT-212 in Treating F - GuruFocus
Solid Biosciences receives FDA orphan drug designation for FA therapy - Investing.com
Solid Biosciences Announces FDA Designations for SGT-212 and Completion of First Dosing in Phase 1b FALCON Trial for Friedreich’s Ataxia - Quiver Quantitative
Solid Biosciences receives FDA orphan drug designation for SGT-212 dual-route gene therapy - marketscreener.com
Solid Biosciences Receives FDA Orphan Drug Designation for - GlobeNewswire
Solid Biosciences (SLDB) Begins Dosing in FALCON Trial for SGT-2 - GuruFocus
Solid Biosciences doses first participant in Friedreich’s ataxia trial - Investing.com
Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia - The Manila Times
Solid Biosciences Doses First Participant in First-In-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia - marketscreener.com
Can Solid Biosciences Inc. stock rebound after recent weaknessWeekly Trading Summary & Real-Time Price Movement Reports - Улправда
Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Solid Biosciences (NASDAQ:SLDB) Shares Down 2.2%Here's What Happened - MarketBeat
Solid Biosciences reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Why one new Solid Biosciences hire is getting 7,000 stock units - Stock Titan
Published on: 2026-01-01 04:47:43 - moha.gov.vn
Aug Reactions: Is Solid Biosciences Inc stock a buy before product launches2025 AllTime Highs & Risk Controlled Stock Pick Alerts - moha.gov.vn
Is Solid Biosciences Inc. stock a buy before product launchesJuly 2025 Setups & Smart Investment Allocation Tips - DonanımHaber
Cartography Biosciences’ CBI-1214 gains IND clearance - BioWorld MedTech
Update Report: Is Solid Biosciences Inc. stock a bargain at current levels2025 Performance Recap & Long-Term Investment Growth Plans - Улправда
Solid Biosciences stock rating reiterated at Market Outperform by Citizens - Investing.com Australia
Gene Therapy Milestones And Collaborations Keep Solid Biosciences In Focus - RTTNews
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services - The Manila Times
Solid Biosciences (SLDB) Sees Duchenne Screening Advancement in US - GuruFocus
Solid Biosciences stock rises after Duchenne added to newborn screening list - Investing.com
Solid Biosciences Supports Duchenne Muscular Dystrophy Inclusion in U.S. Newborn Screening Recommendations - Quiver Quantitative
U.S. newborns will now be screened for Duchenne muscular dystrophy - Stock Titan
Solid Biosciences (SLDB) Gains Attention with Duchenne Muscular Dystrophy Inclusion - GuruFocus
Sarepta's Elevidys Safety Concerns Open Major Opportunity for Solid Biosciences' (SLDB) SGT-003 in Duchenne Therapy - Finviz
Solid Biosciences Inc Stock (SLDB) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.73%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):